Lebwohl M
Department of Dermatology, Mount Sinai Medical Center, New York, New York 10029, USA.
Cutis. 1998 Feb;61(2 Suppl):27-9.
Tazarotene is the first topical retinoid demonstrated to be both effective and tolerable in the treatment of psoriasis. The clinical efficacy and safety of topical tazarotene have been investigated in vehicle-controlled and active-controlled studies. Ongoing studies are evaluating its use in combination with other antipsoriasis medications. Tazarotene has been demonstrated to be significantly more effective than vehicle, and comparable in efficacy to fluocinonide 0.05%, but with a more sustained therapeutic effect after treatment is stopped. Its adverse effects consist primarily of mild to moderate local irritation with no reports of treatment-related systemic adverse effects. Combining tazarotene with a mid- to high-potency corticosteroid gives greater efficacy with fewer adverse effects than either agent used alone. The use of tazarotene in combination with phototherapy or calcipotriene is currently being investigated. Overall, topical tazarotene is a highly useful addition to the array of options available for the topical treatment of mild to moderate plaque psoriasis.
他扎罗汀是首个被证明在治疗银屑病方面既有效又耐受的外用维甲酸类药物。外用他扎罗汀的临床疗效和安全性已在赋形剂对照和活性对照研究中得到调查。正在进行的研究正在评估其与其他抗银屑病药物联合使用的情况。已证明他扎罗汀比赋形剂显著更有效，且在疗效上与0.05%的氟轻松相当，但在停药后具有更持久的治疗效果。其不良反应主要包括轻度至中度局部刺激，未报告与治疗相关的全身性不良反应。与中效至高效皮质类固醇联合使用他扎罗汀比单独使用任何一种药物都具有更高的疗效和更少的不良反应。目前正在研究他扎罗汀与光疗或卡泊三醇联合使用的情况。总体而言，外用他扎罗汀是轻度至中度斑块状银屑病外用治疗可用选项中的一个非常有用的补充。
